沙利度胺对晚期胃癌伴出血患者治疗疗效的研究

黄 菊, 骆玉 霜*
青海大学附属医院

摘要


沙利度胺（Thalidomide）作为一种具有抗血管生成、免疫调节及抗炎作用的多靶点药物，近年来在晚期恶性肿瘤的治疗中逐渐受到关注。晚期胃癌伴出血患者因肿瘤侵袭性强、预后差，且传统化疗或靶向治疗可能加重出血风险，需探索更安全的治疗方案。本文旨在综述沙利度胺在晚期胃癌出血管理中的疗效研究，分析其临床应用的现状、潜在机制及未来的研究方向，为临床实践提供更多的参考。

关键词


沙利度胺；晚期胃癌出血；VEGF；抗血管生成；免疫调节；肿瘤微环境

全文:

PDF


参考


[1]Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022 Feb 9;135(5):584-590. doi: 10.1097/CM9.0000000000002108. PMID: 35143424; PMCID: PMC8920425.

[2]Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, Zeng HM, Wei WW, He J. [Cancer incidence and mortality in China, 2022]. Zhonghua Zhong Liu Za Zhi. 2024 Mar 23;46(3):221-231. Chinese. doi: 10.3760/cma.j.cn112152-20240119-00035.

[3]田乐，丛明华.Ⅲ期胃癌伴急性非手术相关上消化道出血的临床预后特点[C]//亚洲营养学会联合会，中国营养学会.Abstract Book of the 14th Asian Congress of Nutrition--ClinicalNutrition.2023:1.DOI:10.26914/c.cnkihy.2023.077573.

[4]Kiattiweerasak A, Bongkotvirawan P, Aumpan N, Yamaoka Y, Miftahussurur M, Vilaichone RK. Predictive factors and prognosis of upper gastrointestinal bleeding in gastric cancer: A large population-based study (UGIB-GC trial). PLoS One. 2023;18(9):e0291926. Published 2023. doi:10.1371/journal.pone.0291926

[5]Yu J, Jung J, Park SR, et al. Role of palliative radiotherapy in bleeding control in patients with unresectable advanced gastric cancer. BMC Cancer. 2021;21(1):413. Published 2021 Apr 15. doi:10.1186/s12885-021-08145-4

[6]Kiattiweerasak A, Bongkotvirawan P, Aumpan N, Yamaoka Y, Miftahussurur M, Vilaichone RK. Predictive factors and prognosis of upper gastrointestinal bleeding in gastric cancer: A large population-based study (UGIB-GC trial). PLoS One. 2023 Sep 20;18(9):e0291926. doi: 10.1371/journal.pone.0291926. PMID: 37729185; PMCID: PMC10511075.

[7]Kim YI, Choi IJ. Endoscopic management of tumor bleeding from inoperable gastric cancer. Clin Endosc, 48(2), 121-127 (2015).PubMed: 25844339

[8]Park S, Shin JH, Gwon DI et al. Transcatheter Arterial Embolization for Gastrointestinal BleedingAssociated with Gastric Carcinoma: Prognostic Factors Predicting Successful Hemostasis andSurvival. J Vasc Interv Radiol, 28(7), 1012-1021 (2017).

[9]Lee HJ, Shin JH, Yoon HK et al. Transcatheter arterial embolization in gastric cancer patients withacute bleeding. Eur Radiol, 19(4), 960-965 (2009).

[10]刘怡，倪峰，曹广鑫，等.姑息性放射治疗晚期胃癌患者胃出血的临床观察[J].临床肿瘤学杂志，2023，28（10）：935-939.

[11]ZANOTELLI M R, REINHART - KING C A. Mechanical forces in tumor angiogenesis[J]. Adv Exp Med Biol, 2018, 1092:91-112.

[12]Viallard C，Larrivée B.Tumor angiogenesis and vascular normalization: alternative therapeutic targets[J].Angiogenesis， 2017，20（4）:409-426.

[13]Song IJ, Kim HJ, Lee JA, Park JC, Shin SK, Lee SK, Lee YC, Chung H. Clinical Outcomes of Endoscopic Hemostasis for Bleeding in Patients with Unresectable Advanced Gastric Cancer. J Gastric Cancer. 2017 Dec;17(4):374-383. doi: 10.5230/jgc.2017.17.e42.

[14]Aoyama R, Shimomatsuya T, Kubota Y. [A Successfully Treated Case of Emergent Hemorrhage from Unresectable Gastric Cancer with Transcatheter Arterial Embolization]. Gan To Kagaku Ryoho. 2023;50(6):731-734.

[15]Zhou S,Wang F,Hsieh TC,et al.Thalidomide-a notorious sedative to a wonder anticancer drug [J].Electrophoresis,2000,21(15):3270-3279.

[16]庄伟霞，陈莉，王谋锋，等.沙利度胺抗肿瘤机制基础研究分析[J].中国现代药物应用，2022，16（15）：53-57.DOI：10.14164/j.cnki.cn11-5581/r.2022.15.013.

[17]Hao JQ, Hu SY, Zhuang ZX, et al. Distant metastasis in the right inguinal area from gastric cancer: A case report. World J Gastrointest Surg. 2025;17(2):100244. doi:10.4240/wjgs.v17.i2.100244

[18]Luo XF, Luo YH, Zhao XY, et al. Application and progress of palliative therapy in advanced gastric carcinomas. Front Oncol. 13:1104447. Published 2023. doi:10.3389/fonc.2023.1104447

[19]Luo XF, Luo YH, Zhao XY, et al. Application and progress of palliative therapy in advanced gastric carcinomas. Front Oncol. 13:1104447. Published 2023. doi:10.3389/fonc.2023.1104447

[20]Wang J, Yu J, Wang J, et al. Thalidomide combined with chemo-radiotherapy for treating esophageal cancer: A randomized controlled study. Oncol Lett. 2019;18(1):804-813. doi:10.3892/ol.2019.10354

[21]Eder P，Korybalska K，Linke K，et al. Angiogenesis-related proteins-their role in the pathogenesis and treatment of inflammatory bowel disease[J].Curr Protein Pept Sci，2015，16( 3) : 249 - 258.

[22]El Ati Z, Lamia R, Cherif J, et al. Thalidomide-induced bronchiolitis obliterans organizing pneumonia in a patient with multiple myeloma. Saudi J Kidney Dis Transpl. 2019 Jul-Aug;30(4):974-977. doi:10.4103/1319-2442.265477

[23]Barbarossa A, Iacopetta D, Sinicropi MS, Franchini C, Carocci A. Recent Advances in the Development of Thalidomide-Related Compounds as Anticancer Drugs. Curr Med Chem.2022;29(1):19-40.doi:10.2174/0929867328666210623143526

[24]Kotb AR, Abdallah AE, Elkady H, et al. Design, synthesis, anticancer evaluation, and in silico ADMET analysis of novel thalidomide analogs as promising immunomodulatory agents. RSC Adv. 2023;13(16):10488-10502. Published 2023 Apr 3. doi:10.1039/d3ra00066d

[25]Li Q, Zhang C, Ren Y, et al. A novel platelets-related gene signature for predicting prognosis, immune features and drug sensitivity in gastric cancer. Front Immunol. 15:1477427.Published2024.doi:10.3389/fimmu.2024.1477427

[26]Sperling AS, Burgess M, Keshishian H, et al. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019;134(2):160-170.doi:10.1182/blood.2019000789

[27]Smith DA. Teratogenicity is more likely a function of primary and secondary pharmacology than caused by chemically reactive metabolites: a critical evaluation of 40 years of scientific research. Xenobiotica. 2024;54(9):599-608. doi:10.1080/00498254.2024.2366302

[28]Seebauer CT, Wiens B, Hintschich CA, et al. Targeting the microenvironment in the treatmentofarteriovenousmalformations.Angiogenesis.2024;27(1):91-103.doi:10.1007/s10456-023-09896-3

[29]Monteonofrio L, Virdia I, Pozzi S, et al. Molecular mechanisms of thalidomide effectiveness on COVID-19 patients explained: ACE2 is a new ΔNp63α target gene. J MolMed(Berl).2024;102(11):1371-1380.doi:10.1007/s00109-024-02485-x

[30]Chen H, Wu S, Tang M, et al. Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia. N Engl J Med. 2023;389(18):1649-1659. doi:10.1056/NEJMoa2303706

[31]Song K, He K, Yan X, et al. Efficacy and safety of thalidomide in gastrointestinal angiodysplasias: systematic review and meta-analysis with trial sequential analysis of randomized controlled trials. Therap Adv Gastroenterol. 17:17562848241255295. Published2024.doi:10.1177/17562848241255295

[32]Dsouza NN, Alampady V, Baby K, Maity S, Byregowda BH, Nayak Y. Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis. Inflammopharmacology. 2023;31(3):1167-1182.doi:10.1007/s10787-023-01193-1

[33]潘骥群，鲁光平，于志坚.沙利度胺抗肿瘤的研究进展[J].中华肿瘤防治杂志，2012，19（07）：552-555.DOI：10.16073/j.cnki.cjcpt.2012.07.021.

[34]Wang J, Yu J, Wang J, et al. Thalidomide combined with chemo-radiotherapy for treating esophageal cancer: A randomized controlled study. Oncol Lett. 2019;18(1):804-813.

[35]Tao PF, Qian C, Zhou QW, et al. Efficacy and safety of different chemotherapy regimens combined with thalidomide in the treatment of diagnosed HIV-associated diffuse large B-cell lymphoma. Leuk Res Rep. 21:100450. Published 2024. doi:10.1016/j.lrr.2024.100450

[36]Shi J, Xu N, Niu Y, Jia SX, Yang CM, Fang MY. [Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2024;45(1):86-89. doi:10.3760/cma.j.cn121090-20230524-00211

[37]Liu J, Liu D, Wang L. Efficacy analysis of vincristine, adriamycin, dexamethasone chemotherapy regimen combined with thalidomide in the treatment of multiple myeloma nephropathy and its impact on renal function factors. Pak J Pharm Sci. 2025 Jan-Feb;38(1):61-70.

[38]Wang J, Zhang Y, Pan M. Thalidomide as a potential adjuvant treatment for paraneoplastic pemphigus: A single-center experience. Dermatol Ther. 2020;33(6):e14353. doi:10.1111/dth.14353

[39]Was H, Borkowska A, Bagues A, et al. Mechanisms of Chemotherapy-Induced Neurotoxicity.FrontPharmacol.13:750507.Published2022.doi:10.3389/fphar.2022.750507

[40]Li Z, Ding XJ, Qiao X, et al. Thalidomide-based Pt(IV) prodrugs designed to exert synergistic effect of immunomodulation and chemotherapy. J Inorg Biochem. 232:111842.doi:10.1016/j.jinorgbio.2022.111842

[41]Dsouza NN, Alampady V, Baby K, Maity S, Byregowda BH, Nayak Y. Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis. Inflammopharmacology. 2023;31(3):1167-1182.doi:10.1007/s10787-023-01193-1

[42]Harte MC, Saunsbury TA, Hodgson TA. Thalidomide use in the management of oromucosal disease: A 10-year review of safety and efficacy in 12 patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;130(4):398-401. doi:10.1016/j.oooo.2020.06.009

[43]Peng X, Lin ZW, Zhang M, et al. The efficacy and safety of thalidomide in the treatment of refractory Crohn's disease in adults: a double-center, double-blind, randomized-controlled trial. Gastroenterol Rep (Oxf). 10:goac052. Published 2022. doi:10.1093/gastro/goac052

[44]Shi J, Xu N, Niu Y, Jia SX, Yang CM, Fang MY. [Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2024;45(1):86-89. doi:10.3760/cma.j.cn121090-20230524-00211


Refbacks

  • 当前没有refback。